Search
Carteolol
go.drugbank.com/drugs/DB00521ApprovedA beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.
Pimagedine
go.drugbank.com/drugs/DB05383InvestigationalPimagedine has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease.
Isatin
go.drugbank.com/drugs/DB02095ExperimentalIsatin is an indole derivative first obtained by Erdman and Laurent in 1841 as an oxidation product of Indigo dye with nitric acid and chromic acids.
Zelenirstat
go.drugbank.com/drugs/DB15567InvestigationalZelenirstat (PCLX-001) is a first-in-kind N-Myristoyltransferase (NMT) inhibitor being developed by [Pacylex Pharmaceuticals](https://pacylex.com).
Synonyms: 2,6-Dichloro-N-(1,5-dimethyl-3-(2-methylpropyl)-1H-pyrazol-4-yl)-4-(2-(1-piperazinyl)-4-pyridinyl)benzenesulfonamide, 2,6-Dichloro-N-(3-isobutyl-1,5-dimethyl-1H-pyrazol-4-yl)-4-(2-(piperazin-1-yl)pyridin-4-yl)benzenesulfonamideAceprometazine
go.drugbank.com/drugs/DB01615ExperimentalAceprometazine is a is a drug with neuroleptic and anti-histamine properties. Although not widely prescribed, it is used in combination with meprobamate for the treatment of sleep disorders in France under the trade name Mepronizine.
Sulfisoxazole
go.drugbank.com/drugs/DB00263ApprovedVet approvedA short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.
Synonyms: N1-(3,4-dimethyl-5-isoxazolyl)sulfanilamide, N'-(3,4)Dimethylisoxazol-5-yl-sulphanilamideBO-653
go.drugbank.com/drugs/DB19216InvestigationalBO-653 is under investigation in clinical trial NCT00055510 (A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and
RO-5045337
go.drugbank.com/drugs/DB14793InvestigationalRO-5045337 is under investigation in clinical trial NCT01164033 (A Study of RO5045337 in Patients With Solid Tumors).
MORAb-066
go.drugbank.com/drugs/DB17347InvestigationalMORAb-066 is a humanized antibody directed against tissue factor (TF). It is being investigated in pancreatic cancer.
ABX1100
go.drugbank.com/drugs/DB17655InvestigationalIt was first developed by Aro Biotherapeutics and is being investigated for the treatment of Pompe disease.[L45978]